<?xml version="1.0" encoding="UTF-8"?>
<p>For HBV infection, the hypothesis is that high circulating HBsAg levels prevent a proper immune response. A novel mAb, E6F6, is being evaluated for reducing HBsAg levels in patients [
 <xref rid="pntd.0007860.ref052" ref-type="bibr">52</xref>]. In addition, the HBV S protein is being targeted for the discovery of therapeutic mAbs [
 <xref rid="pntd.0007860.ref143" ref-type="bibr">143</xref>].
</p>
